|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Malignant gastric outlet obstruction:Which is the best therapeutic option?显示文摘Malignant gastric outlet obstruction(MGOO)is a clinical condition characterized by the mechanical obstruction of the pylorus or the duodenum due to tumor compression/infiltration,with consequent reduction or impossibility of an adequate oral intake.MGOO is mainly secondary to advanced pancreatic or gastric cancers,and significantly impacts on patients’survival and quality of life.Patients suffering from this condition often present with intractable vomiting and severe malnutrition,which further compromise therapeutic chances.Currently,palliative strategies are based primarily on surgical gastrojejunostomy and endoscopic enteral stenting with self-expanding metal stents.Several studies have shown that surgical approach has the advantage of a more durable relief of symptoms and the need of fewer re-interventions,at the cost of higher procedure-related risks and longer hospital stay.On the other hand,enteral stenting provides rapid clinical improvement,but have the limit of higher stent dysfunction rate due to tumor ingrowth and a subsequent need of frequent reinterventions.Recently,a third way has come from interventional endoscopic ultrasound,through the development of endoscopic ultrasound-guided gastroenterostomy technique with lumen-apposing metal stent.This new technique may ideally encompass the minimal invasiveness of an endoscopic procedure and the long-lasting effect of the surgical gastrojejunostomy,and brought encouraging results so far,even if prospective comparative trial are still lacking.In this Review,we described technical aspects and clinical outcomes of the above-cited therapeutic approaches,and discussed the open questions about the current management of MGOO. | Edoardo Troncone Alessandro Fugazza Annalisa Cappello Giovanna Del Vecchio Blanco Giovanni Monteleone Alessandro Repici Anthony Yuen Bun Teoh Andrea Anderloni | 2020 | World Journal of Gastroenterology2020，26，16： | 7 |
| 2 | Current and future circulating biomarkers for cardiac amyloidosis显示文摘心脏的淀粉样变性病(CA ) 包括影响心肌层的医药条件的一个异构的组。它与严厉,流行和进化的可变的度与 proteinaceous 介绍渗入。尽管有这异质,错误的蛋白质合拢是普通 pathophysiologic 过程,产出日益增多地发展并且最终形成淀粉的纤维的单个错误褶层蛋白质(单体) 的形成。由从起源的机关外面播种,另外,称为 oligomers 的中介转移并且重启这个过程。如此的自我回应的行为象主要的一样使第二等的影响机关重要。不幸地, CA 能在它的自然历史的一个迟了的阶段临床上挑战性、仅仅暗示,让一扇狭窄的治疗学的时间窗户可得到。考虑到淀粉样变性病的进化性质,这里,我们越过 CA 子类型与不同特性和适用性基于时间舞台建议当前使用的 biomarkers 的一个新分类。早标记(免费的轻链,浆液淀粉的 A, 2-microglobulin, osteopontin 和 osteoprotegerin ) 能为疾病察觉被采用。中间的标记[tumorigenicity 的可溶的抑制 2 (sST-2 ) , midregional proadrenomedullin (MR-proADM ) , von Willebrand 因素(vWF ) , hepatocyte 生长因素(HGF ) ,矩阵 metalloproteinases (MMP ) 和织物禁止者 metalloproteinases (TIMP )] 能在心肌的损坏的生物机制上提供信息。作为在心失败,迟了阶段的 biomarkers (troponins 和 natriuretic 肽) 能在 CA 帮助临床医生做好预后和治疗学的反应评估。如此的调查结果在 CA 上为我们的当前的知识产生了一个显著基础。不过,我们想象目标为能够检测合拢缺点的在上游的事件的 biomarkers 的一个未来班,它将最终扩展治疗学的窗户。 | Marco LUCIANI Luca TRONCONE Federica DEL MONTE | 2018 | Acta Pharmacologica Sinica2018，39，7： | 3 |
| 3 | Lumen-apposing metal stents for malignant biliary obstruction: Is this the ultimate horizon of our experience?显示文摘In the last years, endoscopic ultrasonography (EUS) has evolved from a purely diagnostic technique to a more and more complex interventional procedure, with the possibility to perform several type of therapeutic interventions. Among these, EUS-guided biliary drainage (BD) is gaining popularity as a therapeutic approach after failed endoscopic retrograde cholangiopancreatography in distal malignant biliary obstruction (MBO), due to the avoidance of external drainage, a lower rate of adverse events and re-interventions, and lower costs compared to percutaneous trans-hepatic BD. Initially, devices created for luminal procedures (e.g., luminal biliary stents) have been adapted to the new trans-luminal EUSguided interventions, with predictable shortcomings in technical success, outcome and adverse events. More recently, new metal stents specifically designed for transluminal drainage, namely lumen-apposing metal stents (LAMS), have been made available for EUS-guided procedures. An electrocautery enhanced delivery system (EC-LAMS), which allows direct access of the delivery system to the target lumen, has subsequently simplified the classic multi-step procedure of EUS-guided drainages. EUS-BD using LAMS and ECLAMS has been demonstrated effective and safe, and currently seems one of the most performing techniques for EUS-BD. In this Review, we summarize the evolution of the EUS-BD in distal MBO, focusing on the novelty of LAMS and analyzing the unresolved questions about the possible role of EUS as the first therapeutic option to achieve BD in this setting of patients. | Andrea Anderloni Edoardo Troncone Alessandro Fugazza Annalisa Cappello Giovanna Del Vecchio Blanco Giovanni Monteleone Alessandro Repici | 2019 | World Journal of Gastroenterology2019，25，29： | 3 |
| 4 | European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease显示文摘 | S. Husby S. Koletzko I.R. Korponay-Szabó M.L. Mearin A. Phillips R. Shamir R. Troncone K. Giersiepen D. Branski C. Catassi M. Lelgeman M. M?ki C. Ribes-Koninckx A. Ventura K.P. Zimmer | 2012 | Journal of Pediatric Gastroenterology and Nutrition2012，，1： | 2 |
| 5 | European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease显示文摘 | S. Husby S. Koletzko I.R. Korponay-Szabó M.L. Mearin A. Phillips R. Shamir R. Troncone K. Giersiepen D. Branski C. Catassi M. Lelgeman M. M?ki C. Ribes-Koninckx A. Ventura K.P. Zimmer | 2012 | Journal of Pediatric Gastroenterology and Nutrition2012，，1： | 2 |
| 6 | Human leukocyte antigen DQ2/8 prevalence in non-celiac patients with gastrointestinal diseases显示文摘AIM: To investigate the prevalence of human leukocyte antigen (HLA) DQ2/8 alleles in Southern Italians with liver and gastrointestinal (GI) diseases outside of celiac disease. METHODS: HLA DQ2/8 status was assessed in 443 patients from three ambulatory gastroenterology clinics in Southern Italy (University of Federico Ⅱ, Naples, Loreto Crispi Hospital, Ruggi D'Aragona Hospital, Salerno). Patients were grouped based on disease status [pre-post transplant liver disease, esophageal/gastric organic and functional diseases, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD)] and DQ2/8 alleles, which correspond to a celiac disease genetic risk gradient. Subject allele frequencies were compared to healthy Italian controls. RESULTS: One hundred and ninety-six out of four hundred and forty-three (44.2%) subjects, median age 56 years and 42.6% female, were DQ2/8 positive. When stratifying by disease we found that 86/188 (45.7%) patients with liver disease were HLA DQ2/8 positive, 39/73 (53.4%) with functional upper GI diseases and 19/41 (46.3%) with organic upper GI diseases were positive. Furthermore, 38/105 (36.2%) patients with IBS and 14/36 (38.9%) with IBD were HLA DQ2/8 positive (P = 0.21). Compared to healthy controls those with functional upper GI diseases disorders had a 1.8 times higher odds of DQ2/8 positivity. Those with liver disease had 1.3 times the odds, albeit not statistically significant, ofDQ2/8 positivity. Both those with IBS and IBD had a lower odds of DQ2/8 positivity compared to healthy controls. CONCLUSION: The proportion of individuals HLA DQ2/8 positive is higher in those with liver/upper functional GI disease and lower in IBS/IBD as compared to general population estimates. | Daniel DiGiacomo Antonella Santonicola Fabiana Zingone Edoardo Troncone Maria Cristina Caria Patrizia Borgheresi Gianpaolo Parrilli Carolina Ciacci | 2013 | World Journal of Gastroenterology2013，19，16： | 2 |
| 7 | Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice显示文摘 | R. Berni Canani L. Rapacciuolo M.T. Romano L. Tanturri de Horatio G. Terrin F. Manguso P. Cirillo F. Paparo R. Troncone | 2004 | Digestive and Liver Disease2004，，7： | 1 |
| 8 | Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease显示文摘 | R. Berni Canani G. Terrin L. Rapacciuolo E. Miele M.C. Siani C. Puzone L. Cosenza A. Staiano R. Troncone | 2008 | Digestive and Liver Disease2008，，7： | 1 |
| 9 | Glycine as a neurotransmitter in the forebrain:a short review显示文摘 | Hernands M S Troncone L R P | 2009 | J Neural Transm2009，116，： | 1 |
| 10 | Stability analysis of slopes in soils with strain-softening behavior显示文摘 | Conte E Silvestri F Troncone A | 2010 | Computers and Geotechnics2010，37，5： | 1 |
| 11 | Tips and tricks for the diagnosis and management of biliary stenosis-state of the art review显示文摘Biliary stenosis may represent a diagnostic and therapeutic challenge resulting in a delay in diagnosis and initiation of therapy due to the frequent difficulty in distinguishing a benign from a malignant stricture.In such cases,the diagnostic flowchart includes the sequential execution of imaging techniques,such as magnetic resonance,magnetic resonance cholangiopancreatography,and endoscopic ultrasound,while endoscopic retrograde cholangiopancreatography is performed to collect tissue for histopathological/cytological diagnosis or to treat the stenosis by insertion of stent.The execution of percutaneous transhepatic drainage with subsequent biopsy has been shown to increase the possibility of tissue diagnosis after failure of the above techniques.Although the diagnostic yield of histopathology and imaging has increased with improvements in endoscopic ultrasound and peroral cholangioscopy,differential diagnosis between malignant and benign stenosis may not be easy in some patients,and strictures are classified as indeterminate.In these cases,a multidisciplinary workup including biochemical marker assays and advanced technologies available may speed up a diagnosis of malignancy or avoid unnecessary surgery in the event of a benign stricture.Here,we review recent advancements in the diagnosis and management of biliary strictures and describe tips and tricks to increase diagnostic yields in clinical routine. | Giovanna Del Vecchio Blanco Michelangela Mossa Edoardo Troncone Renato Argirò Andrea Anderloni Alessandro Repici Omero Alessandro Paoluzi Giovanni Monteleone | 2021 | World Journal of Gastrointestinal Endoscopy2021，13，10： | 1 |
| 12 | Detection of BRAF mutation in thyroid papillm'y carcinoma by mutant allele-specific PCR amplification (MASA)显示文摘 | Sapio M R Posca D Troncone G | 2006 | EurJ Endoerinol2006，154，2： | 1 |
| 13 | Cytological and moleeular diagnosis of solid variant of papillary thyroid carcinoma: a case report显示文摘 | Troncone G Russo M Malapelle U | 2008 | CytoJouma]2008，5，： | 1 |
| 14 | Leiomyomatosis of the oesophagus 显示文摘 | Fitzgerald JF Troncone R Ahmed M | 2004 | J Pediatr Gastroenterol Nutr2004，39，2： | 1 |
| 15 | Progressive failure analysis of shallow foundations on soils with strain-softening behaviour显示文摘 | E. Conte A. Donato A. Troncone | 2013 | Computers and Geotechnics2013，，： | 1 |
| 16 | Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-hodgkin lymphoma: a critical review of 307 cases with technical suggestions显示文摘 | Zeppa P Marino G Troncone G | 2004 | Cancer Cytopathology2004，102，1： | 1 |
| 17 | 显示文摘 | Troncon LEA | 1992 | Gut1992，，： | 1 |
| 18 | The optimal diagnostic workup for children with suspected food allergy显示文摘 | Berni Canani R Di Costanzo M Troncone R | | 0，，10： | 1 |
| 19 | C-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer 显示文摘 | Troncone G Panico L Vetrani A | 1996 | Diagn Cytopathol1996，14，2： | 1 |
| 20 | Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA) 显示文摘 | Sapio MR Posca D Troncone G | 2006 | Eur J Endocrinol2006，154，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员